Skip to main content
Premium Trial:

Request an Annual Quote

SensiGen, University of Michigan, Nanogen, Frutarom Industries, Ramot at Tel Aviv University

SensiGen Exclusively Licenses Lupus Biomarkers From U of Mich
SensiGen has acquired an option from the University of Michigan to exclusively license a set of epigenetic biomarkers for early detection and monitoring of lupus, the company said last week.
The technology, developed by University of Michigan professor of medicine Bruce Richardson, includes a patented panel of biomarkers for epigenetic variations of genes uniquely associated with lupus along with related research assays.
Richardson, who is also chief of rheumatology at Ann Arbor Veterans Hospital, discovered that the levels of methylation of certain genes were closely associated with the onset of lupus, and developed a set of biomarkers to identify their presence.
SensiGen said that it intends to develop commercial diagnostic assays for the biomarkers using its AttoSense technology.
Financial terms of the agreement were not disclosed.

Nanogen Licenses Schizophrenia Markers From Australian Institutes
Nanogen last week said that it has acquired the rights to genetic markers related to schizophrenia and responses to anti-psychotic therapies from the Co-operative Research Center for Diagnostics and Queensland University of Technology in Australia.
Nanogen said that it plans to use the markers to create diagnostic tests for schizophrenia and related conditions. Some of the markers may help predict adverse drug reactions and therefore guide therapeutic decision making, Nanogen said.
Financial terms of the agreement were not disclosed.

Frutarom Licenses Methods to Produce Natural Anti-Viral Extract From Tel Aviv University
Frutarom Industries and Ramot at Tel Aviv University last week said that they have signed an exclusive agreement to commercialize patent-pending methods developed by a Tel Aviv University professor to produce an antiviral extract from cinnamon.
Under the terms of the agreement, Ramot, the technology-transfer arm of Tel Aviv University, has granted Frutarom an exclusive global license to commercialize know-how in order to manufacture and market the natural extract.
Frutarom will invest in further research and development of the product and additional applications to be led by Michael Ovadia, a Tel Aviv University professor and main inventor of the technology.
Ovadia and colleagues demonstrated the extract’s ability to rapidly neutralize a broad range of viruses that cause infectious diseases in humans and animals, such as human and avian influenza, herpes simplex virus 1, and HIV. The researchers also demonstrated the extract’s ability to serve as a vaccination agent in chicken embryos infected with Newcastle disease virus.
Financial terms of the agreement were not disclosed.